NO329381B1 - Blandinger for nasal administrasjon for behandling av ereksjonsproblemer eller Parkinsons sykdom - Google Patents

Blandinger for nasal administrasjon for behandling av ereksjonsproblemer eller Parkinsons sykdom Download PDF

Info

Publication number: NO329381B1
Authority: NO; Norway
Prior art keywords: mixture; accordance; drug; treatment; nasal
Prior art date: 1997-12-02

Application number

NO20002851A

Other languages

English (en)

Norwegian (no)

Other versions

NO20002851L (no

NO20002851D0 (no

Inventor

Lisbeth Illum

Peter Watts

Original Assignee

Archimedes Dev Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-02

Filing date

2000-06-02

Publication date

2010-10-04

1997-12-02 Priority claimed from GBGB9725519.4A external-priority patent/GB9725519D0/en

1998-03-13 Priority claimed from GBGB9805253.3A external-priority patent/GB9805253D0/en

2000-06-02 Application filed by Archimedes Dev Ltd filed Critical Archimedes Dev Ltd

2000-06-02 Publication of NO20002851L publication Critical patent/NO20002851L/no

2000-06-02 Publication of NO20002851D0 publication Critical patent/NO20002851D0/no

2010-10-04 Publication of NO329381B1 publication Critical patent/NO329381B1/no

Links

239000000203 mixture Substances 0.000 title claims abstract description 108
238000011282 treatment Methods 0.000 title claims description 32
208000018737 Parkinson disease Diseases 0.000 title claims description 6
201000001881 impotence Diseases 0.000 title abstract description 8
208000010228 Erectile Dysfunction Diseases 0.000 title abstract description 7
239000003814 drug Substances 0.000 claims abstract description 121
230000036470 plasma concentration Effects 0.000 claims abstract description 24
230000002459 sustained effect Effects 0.000 claims abstract description 7
241000124008 Mammalia Species 0.000 claims abstract 3
229940079593 drug Drugs 0.000 claims description 113
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 60
229960004046 apomorphine Drugs 0.000 claims description 60
239000004005 microsphere Substances 0.000 claims description 46
239000001814 pectin Substances 0.000 claims description 30
229920001277 pectin Polymers 0.000 claims description 30
235000010987 pectin Nutrition 0.000 claims description 30
239000007788 liquid Substances 0.000 claims description 29
229920002148 Gellan gum Polymers 0.000 claims description 28
239000000546 pharmaceutical excipient Substances 0.000 claims description 27
230000000694 effects Effects 0.000 claims description 24
229920001282 polysaccharide Polymers 0.000 claims description 23
239000005017 polysaccharide Substances 0.000 claims description 23
230000001856 erectile effect Effects 0.000 claims description 22
150000004804 polysaccharides Chemical class 0.000 claims description 21
229920001400 block copolymer Polymers 0.000 claims description 19
239000000463 material Substances 0.000 claims description 18
239000000843 powder Substances 0.000 claims description 16
-1 polyoxyethylene Polymers 0.000 claims description 14
150000001768 cations Chemical class 0.000 claims description 13
150000001875 compounds Chemical class 0.000 claims description 13
210000003928 nasal cavity Anatomy 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 12
229920002472 Starch Polymers 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 8
238000005342 ion exchange Methods 0.000 claims description 8
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 8
239000008107 starch Substances 0.000 claims description 8
235000019698 starch Nutrition 0.000 claims description 8
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 7
235000010443 alginic acid Nutrition 0.000 claims description 7
229920000615 alginic acid Polymers 0.000 claims description 7
229920001586 anionic polysaccharide Polymers 0.000 claims description 7
150000004836 anionic polysaccharides Chemical class 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
239000012528 membrane Substances 0.000 claims description 7
101150049660 DRD2 gene Proteins 0.000 claims description 6
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims description 6
239000002464 receptor antagonist Substances 0.000 claims description 6
229940044551 receptor antagonist Drugs 0.000 claims description 6
BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 5
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
229940124639 Selective inhibitor Drugs 0.000 claims description 4
239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
230000002860 competitive effect Effects 0.000 claims description 4
230000006870 function Effects 0.000 claims description 4
210000005036 nerve Anatomy 0.000 claims description 4
229920001983 poloxamer Polymers 0.000 claims description 4
229940076279 serotonin Drugs 0.000 claims description 4
230000001839 systemic circulation Effects 0.000 claims description 4
229920001285 xanthan gum Polymers 0.000 claims description 4
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 claims description 3
229930008281 A03AD01 - Papaverine Natural products 0.000 claims description 3
229920001661 Chitosan Polymers 0.000 claims description 3
QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 claims description 3
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims description 3
102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 claims description 3
108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 claims description 3
239000005557 antagonist Substances 0.000 claims description 3
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 claims description 3
230000000903 blocking effect Effects 0.000 claims description 3
229920002674 hyaluronan Polymers 0.000 claims description 3
229960003160 hyaluronic acid Drugs 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
229960001789 papaverine Drugs 0.000 claims description 3
229960003418 phenoxybenzamine Drugs 0.000 claims description 3
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 claims description 3
229960001999 phentolamine Drugs 0.000 claims description 3
229960003310 sildenafil Drugs 0.000 claims description 3
229960000317 yohimbine Drugs 0.000 claims description 3
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims description 3
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 claims description 3
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
229930064664 L-arginine Natural products 0.000 claims description 2
235000014852 L-arginine Nutrition 0.000 claims description 2
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 2
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 2
229940126601 medicinal product Drugs 0.000 claims 5
239000002160 alpha blocker Substances 0.000 claims 1
238000010668 complexation reaction Methods 0.000 claims 1
229920001987 poloxamine Polymers 0.000 claims 1
239000000243 solution Substances 0.000 description 30
238000009472 formulation Methods 0.000 description 18
238000000034 method Methods 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
238000013461 design Methods 0.000 description 13
238000009792 diffusion process Methods 0.000 description 9
229920000642 polymer Polymers 0.000 description 9
238000010521 absorption reaction Methods 0.000 description 8
238000001879 gelation Methods 0.000 description 8
239000000499 gel Substances 0.000 description 7
210000004379 membrane Anatomy 0.000 description 6
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
229920002310 Welan gum Polymers 0.000 description 5
229940072056 alginate Drugs 0.000 description 5
239000002585 base Substances 0.000 description 5
238000013270 controlled release Methods 0.000 description 5
210000004072 lung Anatomy 0.000 description 5
239000000126 substance Substances 0.000 description 5
229910021642 ultra pure water Inorganic materials 0.000 description 5
239000012498 ultrapure water Substances 0.000 description 5
206010067484 Adverse reaction Diseases 0.000 description 4
241000700159 Rattus Species 0.000 description 4
230000006838 adverse reaction Effects 0.000 description 4
239000012062 aqueous buffer Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
239000012530 fluid Substances 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
230000008569 process Effects 0.000 description 4
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 3
235000010418 carrageenan Nutrition 0.000 description 3
229920001525 carrageenan Polymers 0.000 description 3
239000000679 carrageenan Substances 0.000 description 3
229940113118 carrageenan Drugs 0.000 description 3
229960002086 dextran Drugs 0.000 description 3
239000012669 liquid formulation Substances 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
229940100656 nasal solution Drugs 0.000 description 3
229940097496 nasal spray Drugs 0.000 description 3
239000007922 nasal spray Substances 0.000 description 3
229960002715 nicotine Drugs 0.000 description 3
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
210000001331 nose Anatomy 0.000 description 3
229920001992 poloxamer 407 Polymers 0.000 description 3
229940044476 poloxamer 407 Drugs 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
241000588986 Alcaligenes Species 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
206010024769 Local reaction Diseases 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
125000000129 anionic group Chemical group 0.000 description 2
239000011324 bead Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
125000005594 diketone group Chemical group 0.000 description 2
238000004945 emulsification Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
230000010352 nasal breathing Effects 0.000 description 2
229920005615 natural polymer Polymers 0.000 description 2
230000035699 permeability Effects 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
229960000502 poloxamer Drugs 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
238000012552 review Methods 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
235000010413 sodium alginate Nutrition 0.000 description 2
239000000661 sodium alginate Substances 0.000 description 2
229940005550 sodium alginate Drugs 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 1
SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
UMHJEEQLYBKSAN-UHFFFAOYSA-N Adipaldehyde Chemical compound O=CCCCCC=O UMHJEEQLYBKSAN-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241001474374 Blennius Species 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
206010006784 Burning sensation Diseases 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
125000003535 D-glucopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
125000003423 D-mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
229920000045 Dermatan sulfate Polymers 0.000 description 1
QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
206010013911 Dysgeusia Diseases 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
241001134784 Furcellariaceae Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241001147462 Gigartinaceae Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
241001428260 Hypneaceae Species 0.000 description 1
IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical compound O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 description 1
229920000161 Locust bean gum Polymers 0.000 description 1
WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
101100388055 Mus musculus Polm gene Proteins 0.000 description 1
206010028748 Nasal obstruction Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033546 Pallor Diseases 0.000 description 1
229920002230 Pectic acid Polymers 0.000 description 1
241001134798 Phyllophoraceae Species 0.000 description 1
229920000148 Polycarbophil calcium Polymers 0.000 description 1
229920000388 Polyphosphate Polymers 0.000 description 1
241001282135 Poromitra oscitans Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
241001428151 Solieriaceae Species 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010047513 Vision blurred Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
241000589634 Xanthomonas Species 0.000 description 1
206010048232 Yawning Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940023476 agar Drugs 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229940003824 apomorphine 10 mg/ml Drugs 0.000 description 1
229960003990 apomorphine hydrochloride Drugs 0.000 description 1
239000000823 artificial membrane Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
239000000227 bioadhesive Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
229940096529 carboxypolymethylene Drugs 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
235000020971 citrus fruits Nutrition 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
238000004581 coalescence Methods 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000008021 deposition Effects 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
238000010586 diagram Methods 0.000 description 1
208000013219 diaphoresis Diseases 0.000 description 1
125000000600 disaccharide group Chemical group 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000000835 electrochemical detection Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
239000008151 electrolyte solution Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
229940015043 glyoxal Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
238000001794 hormone therapy Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229940118019 malondialdehyde Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000010297 mechanical methods and process Methods 0.000 description 1
230000005226 mechanical processes and functions Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000003232 mucoadhesive effect Effects 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
239000004482 other powder Substances 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
150000002924 oxiranes Chemical class 0.000 description 1
125000006353 oxyethylene group Chemical group 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
210000003899 penis Anatomy 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229950005134 polycarbophil Drugs 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
239000001205 polyphosphate Substances 0.000 description 1
235000011176 polyphosphates Nutrition 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004202 respiratory function Effects 0.000 description 1
239000002002 slurry Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
239000004296 sodium metabisulphite Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
150000004044 tetrasaccharides Chemical class 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
229920000428 triblock copolymer Polymers 0.000 description 1
150000004043 trisaccharides Chemical group 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Otolaryngology (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Psychology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO20002851A 1997-12-02 2000-06-02 Blandinger for nasal administrasjon for behandling av ereksjonsproblemer eller Parkinsons sykdom NO329381B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9725519.4A GB9725519D0 (en)	1997-12-02	1997-12-02	Nasal formulation
GBGB9805253.3A GB9805253D0 (en)	1998-03-13	1998-03-13	Nasal formulation
PCT/GB1998/003572 WO1999027905A1 (en)	1997-12-02	1998-11-27	Compositions for nasal administration

Publications (3)

Publication Number	Publication Date
NO20002851L NO20002851L (no)	2000-06-02
NO20002851D0 NO20002851D0 (no)	2000-06-02
NO329381B1 true NO329381B1 (no)	2010-10-04

Family

ID=26312701

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20002851A NO329381B1 (no)	1997-12-02	2000-06-02	Blandinger for nasal administrasjon for behandling av ereksjonsproblemer eller Parkinsons sykdom

Country Status (13)

Country	Link
US (2)	US6342251B1 (de)
EP (1)	EP1035833B1 (de)
JP (2)	JP4754067B2 (de)
AR (1)	AR017694A1 (de)
AT (1)	ATE303131T1 (de)
AU (1)	AU751182B2 (de)
CA (1)	CA2312839C (de)
DE (1)	DE69831421T2 (de)
DK (1)	DK1035833T3 (de)
ES (1)	ES2249846T3 (de)
NO (1)	NO329381B1 (de)
NZ (1)	NZ504786A (de)
WO (1)	WO1999027905A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6566368B2 (en) *	1994-04-22	2003-05-20	Pentech Pharmaceuticals, Inc.	Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US7022683B1 (en) *	1998-05-13	2006-04-04	Carrington Laboratories, Inc.	Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
TWI223598B (en) *	1998-06-22	2004-11-11	Pfizer Ireland Pharmaceuticals	An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6200591B1 (en) *	1998-06-25	2001-03-13	Anwar A. Hussain	Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
DE19834506A1 (de) *	1998-07-31	2000-02-03	Hexal Ag	Transmucosales therapeutisches System zur Anwendung von Sildenafil
DE19834507A1 (de) *	1998-07-31	2000-02-03	Hexal Ag	Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
US20020002175A1 (en) *	2000-09-19	2002-01-03	Charanjit Behl	Nasal delivery of apomorphine in combination with glycol derivatives
US6436950B1 (en)	1998-08-14	2002-08-20	Nastech Pharmaceutical Company, Inc.	Nasal delivery of apomorphine
KR20020015310A (ko) *	1999-04-06	2002-02-27	로버트 엘. 로브	신체적인 성적반응을 변화시키는 방법
US6632419B2 (en) *	1999-05-04	2003-10-14	Aradigm Corporation	Increasing libido in humans via acute testosterone administration
US7258850B2 (en) *	1999-05-04	2007-08-21	Aradigm Corporation	Methods and compositions for treating erectile dysfunction
BR0005797A (pt) *	2000-03-20	2001-10-16	Abbott Lab	Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
US6506765B2 (en)	2000-04-07	2003-01-14	Tap Pharmaceutical Products, Inc.	Apomorphine derivatives and methods for their use
US6565851B2 (en) *	2000-05-26	2003-05-20	Horphag Research Limited	Relieving symptoms of erectile dysfunction with proanthocyanidins
US6777000B2 (en) *	2001-02-28	2004-08-17	Carrington Laboratories, Inc.	In-situ gel formation of pectin
US7494669B2 (en)	2001-02-28	2009-02-24	Carrington Laboratories, Inc.	Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
CN1543338B (zh)	2001-08-16	2010-06-16	Cmp医疗有限公司	壳多糖微粒及其医疗用途
US7666876B2 (en)	2002-03-19	2010-02-23	Vernalis (R&D) Limited	Buprenorphine formulations for intranasal delivery
AU2003234090A1 (en) *	2002-04-11	2003-10-27	Medimmune Vaccines, Inc.	Spray freeze dry of compositions for pulmonary administration
AU2003230908A1 (en) *	2002-04-11	2003-10-27	Medimmune Vaccines, Inc.	Spray freeze dry of compositions for intranasal administration
WO2004003145A2 (en) *	2002-06-28	2004-01-08	Nastech Pharmaceutical Company Inc.	Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
GB0300531D0 (en)	2003-01-10	2003-02-12	West Pharm Serv Drug Res Ltd	Pharmaceutical compositions
GB0304636D0 (en) *	2003-02-28	2003-04-02	Britannia Pharmaceuticals Ltd	Pharmaceutical composition for nasal delivery
US20040204439A1 (en) *	2003-04-14	2004-10-14	Staniforth John Nicholas	Composition, device, and method for treating sexual dysfunction via inhalation
RU2364400C2 (ru) *	2003-04-14	2009-08-20	Вектура Лтд	Фармацевтические композиции
CA2523870A1 (en) *	2003-04-30	2004-11-18	Nastech Pharmaceutical Company Inc.	Claudins' underexpression as markers of tumor metastasis
US20050090518A1 (en) *	2003-10-24	2005-04-28	Nastech Pharmaceutical Company Inc.	Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
US20050129679A1 (en) *	2003-12-15	2005-06-16	Nastech Pharmaceutical Company Inc.	Method for opening tight junctions
US7297786B2 (en)	2004-07-09	2007-11-20	University Of Iowa Research Foundation	RNA interference in respiratory epitheial cells
US20070110788A1 (en) *	2005-11-14	2007-05-17	Hissong James B	Injectable formulation capable of forming a drug-releasing device
AU2007285472B2 (en) *	2006-03-30	2013-10-24	Engene, Inc.	Non-viral compositions and methods for transfecting gut cells in vivo
JP5185109B2 (ja)	2006-04-21	2013-04-17	東興薬品工業株式会社	スプレー用ゲルタイプ皮膚・粘膜付着型製剤およびそれを用いた投与システム
GB2437488A (en) *	2006-04-25	2007-10-31	Optinose As	Pharmaceutical oily formulation for nasal or buccal administration
US7976873B2 (en) *	2006-05-10	2011-07-12	Medtronic Xomed, Inc.	Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7959943B2 (en) *	2006-05-10	2011-06-14	Medtronics Xomed, Inc.	Solvating system and sealant for medical use in the middle or inner ear
US20070264296A1 (en) *	2006-05-10	2007-11-15	Myntti Matthew F	Biofilm extracellular polysachharide solvating system
US7993675B2 (en)	2006-05-10	2011-08-09	Medtronic Xomed, Inc.	Solvating system and sealant for medical use in the sinuses and nasal passages
US8088095B2 (en) *	2007-02-08	2012-01-03	Medtronic Xomed, Inc.	Polymeric sealant for medical use
GB0715285D0 (en) *	2007-08-06	2007-09-12	Britannia Pharmaceuticals Ltd	Improvements in or relating to powdered medicaments for nasal delivery
WO2009040595A1 (en) *	2007-09-28	2009-04-02	Wockhardt Research Centre	Multi-dose pharmaceutical composition of analgesic for nasal administration
GB0721394D0 (en) *	2007-10-31	2007-12-12	Vectura Group Plc	Compositions for trating parkinson's disease
EP2057982A1 (de) *	2007-11-09	2009-05-13	Archimedes Development Limited	Intranasale Zusammensetzungen
US9198997B2 (en)	2008-04-24	2015-12-01	Medtronic, Inc.	Rehydratable thiolated polysaccharide particles and sponge
EP2296637B1 (de)	2008-04-24	2014-04-02	Medtronic, Inc	Chitosan enthaltende schutz-zusammensetzung
EP2310002B1 (de) *	2008-04-24	2016-11-02	Medtronic, Inc	Schutzgel auf basis von chitosan und oxidiertem polysaccharid
EP2288389B1 (de)	2008-04-24	2014-06-11	Medtronic, Inc	Kaltsterilisation mit ionisierender strahlung
US8784790B2 (en)	2008-06-12	2014-07-22	Medtronic Xomed, Inc.	Method for treating chronic wounds with an extracellular polymeric substance solvating system
US8580801B2 (en)	2008-07-23	2013-11-12	Robert I. Henkin	Phosphodiesterase inhibitor treatment
US20100086576A1 (en) *	2008-10-06	2010-04-08	Myntti Matthew F	Antimicrobial composition and methods of making and using same
CZ302789B6 (cs)	2009-11-25	2011-11-09	Zentiva, K. S.	Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
US10653133B2 (en)	2011-05-10	2020-05-19	Next Science IP Holdings Pty Ltd	Antimicrobial solid and methods of making and using same
MX2016001030A (es)	2013-07-23	2016-10-07	Allergan Inc	Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
US10598672B2 (en)	2014-02-18	2020-03-24	Cyrano Therapeutics, Inc.	Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
ES2923438T3 (es) *	2014-11-20	2022-09-27	Serenity Pharmaceuticals Llc	Composiciones que comprenden bajas dosis de desmopresina en combinación con un antagonista del receptor alfaadrenérgico
FR3032618A1 (fr) *	2015-02-12	2016-08-19	Laboratoires Chemineau	Composition a base de plantes de la famille des malvaceae pour une administration dans la cavite nasale
EP3056219B1 (de) *	2015-02-12	2018-08-22	Laboratoires Chemineau	Zusammensetzung auf pflanzenbasis der familie der malvengewächse (malvaceae) zur verabreichung auf schleimhäuten
WO2017168174A1 (en)	2016-04-02	2017-10-05	N4 Pharma Uk Limited	New pharmaceutical forms of sildenafil
WO2021194893A1 (en)	2020-03-24	2021-09-30	Cyrano Therapeutics, Inc.	Treatment of chemosensory dysfunction from a coronavirus infection
KR20240134157A (ko) *	2022-01-06	2024-09-06	시라노 테라퓨틱스, 아이엔씨.	파킨슨 치료제의 개선된 코 투여

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS62123112A (ja)	1985-11-22	1987-06-04	Sunstar Inc	軟膏基剤
DE3601132A1 (de)	1986-01-16	1987-07-23	Christian Bannert	Verfahren zur behandlung der schleimhaut
JPS62236862A (ja)	1986-04-09	1987-10-16	Nippon Kayaku Co Ltd	人工粘液
WO1988004926A1 (en) *	1987-01-08	1988-07-14	Nastech Pharmaceutical Company, Inc.	Nasal delivery of amino acids
US4826683A (en) *	1987-01-09	1989-05-02	Bates Harry L	Decongestant
FR2614021B1 (fr) *	1987-04-14	1991-03-01	Andre Buzas	Derives de la 1-((1,1-diphenyl)-1-alcenyl)-piperazine, procede d'obtention et compositions pharmaceutiques les contenant
US4915948A (en)	1987-08-31	1990-04-10	Warner-Lambert Company	Tablets having improved bioadhesion to mucous membranes
DE3827561C1 (de)	1988-08-13	1989-12-28	Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5707644A (en) *	1989-11-04	1998-01-13	Danbiosyst Uk Limited	Small particle compositions for intranasal drug delivery
JPH0436233A (ja) *	1990-05-29	1992-02-06	Biomaterial Universe Kk	生理活性物質含有生体内分解吸収性の徐放性製剤
JPH0597706A (ja)	1991-04-09	1993-04-20	Chemex Block Drug Jv	アフタ性潰瘍および他の粘膜皮膚障害の処置方法
IT1250691B (it) *	1991-07-22	1995-04-21	Giancarlo Santus	Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
US5318780A (en)	1991-10-30	1994-06-07	Mediventures Inc.	Medical uses of in situ formed gels
DE69434304T2 (de) *	1993-03-26	2005-12-29	Merkus, Franciscus Wilhelmus H.M.	Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
EP0696919B1 (de) *	1993-04-05	2002-01-30	Competitive Technologies, Inc.	Diagnose und behandlung von erektilen funktionsstörungen
NZ250844A (en) *	1993-04-07	1996-03-26	Pfizer	Treatment of non-insulin dependant diabetes with peptides; composition
GB9310412D0 (en) *	1993-05-20	1993-07-07	Danbiosyst Uk	Nasal nicotine system
WO1995002416A1 (en) *	1993-07-12	1995-01-26	Virus Research Institute	Hydrogel microencapsulated vaccines
JP3696265B2 (ja) *	1994-02-04	2005-09-14	日本オルガノン株式会社	点鼻液剤
CA2188385C (en) *	1994-04-22	2000-07-11	Ragab El-Rashidy	Dosage forms and method for ameliorating male erectile dysfunction
GB9414966D0 (en) *	1994-07-26	1994-09-14	Danbiosyst Uk	Pharmaceutical compositions for the nasal administration of antiviral agents
GB9707934D0 (en) *	1997-04-18	1997-06-04	Danbiosyst Uk	Improved delivery of drugs to mucosal surfaces

1998
- 1998-11-27 EP EP98955814A patent/EP1035833B1/de not_active Expired - Lifetime
- 1998-11-27 AT AT98955814T patent/ATE303131T1/de active
- 1998-11-27 WO PCT/GB1998/003572 patent/WO1999027905A1/en not_active Ceased
- 1998-11-27 AR ARP980106027A patent/AR017694A1/es unknown
- 1998-11-27 ES ES98955814T patent/ES2249846T3/es not_active Expired - Lifetime
- 1998-11-27 NZ NZ504786A patent/NZ504786A/en not_active IP Right Cessation
- 1998-11-27 JP JP2000522892A patent/JP4754067B2/ja not_active Expired - Fee Related
- 1998-11-27 AU AU12535/99A patent/AU751182B2/en not_active Ceased
- 1998-11-27 DE DE69831421T patent/DE69831421T2/de not_active Expired - Lifetime
- 1998-11-27 DK DK98955814T patent/DK1035833T3/da active
- 1998-11-27 CA CA002312839A patent/CA2312839C/en not_active Expired - Fee Related
2000
- 2000-06-02 US US09/586,139 patent/US6342251B1/en not_active Expired - Lifetime
- 2000-06-02 NO NO20002851A patent/NO329381B1/no not_active IP Right Cessation
2001
- 2001-08-01 US US09/920,698 patent/US20010046519A1/en not_active Abandoned
2010
- 2010-10-07 JP JP2010227620A patent/JP2011026341A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
AU1253599A (en)	1999-06-16
JP2001524509A (ja)	2001-12-04
DK1035833T3 (da)	2006-01-09
US20010046519A1 (en)	2001-11-29
DE69831421D1 (de)	2005-10-06
US6342251B1 (en)	2002-01-29
CA2312839A1 (en)	1999-06-10
ATE303131T1 (de)	2005-09-15
AR017694A1 (es)	2001-09-12
DE69831421T2 (de)	2006-06-22
NO20002851L (no)	2000-06-02
JP2011026341A (ja)	2011-02-10
CA2312839C (en)	2008-01-15
NZ504786A (en)	2005-07-29
EP1035833B1 (de)	2005-08-31
EP1035833A1 (de)	2000-09-20
ES2249846T3 (es)	2006-04-01
NO20002851D0 (no)	2000-06-02
WO1999027905A1 (en)	1999-06-10
JP4754067B2 (ja)	2011-08-24
AU751182B2 (en)	2002-08-08

Legal Events

Date	Code	Title	Description
2016-06-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US6342251B1 (en)	2002-01-29	Compositions for nasal administration
US5935604A (en)	1999-08-10	Nasal drug delivery composition containing nicotine
JP4880657B2 (ja)	2012-02-22	粘膜表面への改良された薬物供給
Van der Merwe et al.	2004	Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs
AU2003216842B2 (en)	2007-12-13	Formulation comprising buprenorphine
AU757786B2 (en)	2003-03-06	Formulations of fexofenadine
Holte et al.	2003	Sustained release of water-soluble drug from directly compressed alginate tablets
JPH07503481A (ja)	1995-04-13	オピオイド鎮痛剤の極性代謝物を含有する鼻腔投与用組成物
CN107921033B (zh)	2021-01-01	供鼻内给药的格拉斯琼的生物粘着性组成物
EA008500B1 (ru)	2007-06-29	Фармацевтическая композиция
WO2005079749A2 (en)	2005-09-01	Chitosan containing solution
Mokhtare et al.	2017	In vitro and in vivo evaluation of alginate and alginatechitosan beads containing metformin hydrochloride
Tatykhanova et al.	2020	Mucoadhesive properties of gellan and its modified derivatives
RS58119B1 (sr)	2019-02-28	Kompozicije jedinjenja tiakumicina
Singh et al.	2020	Harmonious biomaterials for development of in situ approaches for locoregional delivery of anti-cancer drugs: current trends
EP2266596B1 (de)	2014-07-02	Pharmazeutische zusammensetzung und verfahren zu ihrer herstellung
Rajeshkumar et al.	2023	AN EXTENSIVE REVIEW ON OPTHALMIC IN SITU GELLING SYSTEM
CN121422120A (zh)	2026-01-30	基于茶乳酪的胃酸与体温双响应水溶胶体系及制备方法和在制备治疗胃溃疡药物中的应用